Vascular endothelial growth factor and retinal neovascularisation: A new therapeutic approach for diabetic retinopathy;VEGF et neovascularisation retinienne: Une approche therapeutique nouvelle de la retinopathie diabetique

Diabetes and Metabolism

Volumn 22, Issue 4, 1996, Pages 268-273

  Favard, C ^a   Ortega, N ^b   Bayard, F ^c   Plouet, J ^b  

^a HÔTEL DIEU   (France)

^b CNRS   (France)

^c CHU RANGUEIL   (France)

Author keywords

diabetic retinopathy; retinal revascularization fibroblast growth factor; vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; VASCULOTROPIN;

ARTICLE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; HUMAN; NONHUMAN; RETINA NEOVASCULARIZATION;

ANIMALS; BIOLOGICAL AVAILABILITY; DIABETIC RETINOPATHY; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, GROWTH FACTOR; RETINAL VESSELS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030035243     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK, 1948, 68, 137-180.
2. Ashton N. Retinal vascularization in health and disease. Am J Ophthalmol, 1957, 44, 7-24.
3. Barritault D, Plouët J, Courtois Y. Purification, characterization and biological properties of the eye-derived growth factor from retina. Analogies with brain-derived growth factor. J Neurosc Res, 1982, 8, 477-490.
4. Romquin N, Plouët J, Barritault D, Courtois Y. Human and bovine vascular endothelial cells. Comparative effects on cell growth and longevity of an eye-derived growth factor (EDGF) and of extracellular matrix. Biol Cell, 1983, 49, 104-108.
5. Glaser BM, D'Amore PA, Michels RG. Demonstration of vasoproliferative activity from mammalian retina. J Cell Biol, 1980, 84, 298-304.
6. D'Amore PA, Glaser BM, Bruson SK, Fenselau AH. Angiogenic activity from bovine retina : partial purification and characterization. Proc Natl Acad Sci USA, 1981, 78, 3068-3072.
7. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med., 1995, 1, 27-30.
8. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type a, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci, 1987, 84, 5277-5281.
9. Mergia A, Eddy R, Abraham JA. The genes for basic and acidic fibroblast growth factors are on different human chromosomes. Biochem Biophys Res Commun. 1986, 138, 644-65.
10. Abraham JA, Mergia A, Whang JL et al. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science, 1986, 233, 545-548.
11. Plouët J, Gospodarowicz D. Iris-derived melanocytes contain a growth factor that resembles basic fibroblast growth factor. Exp Eye Res, 1990, 51, 519-529.
12. Prats H, Kaghad M, Prats AC et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. Proc Natl Acad Sci, 1989, 86, 1836-1840.
13. Gajduseck CM, Carbon S. Injury induced release of basic fibroblast growth factor from bovine aortic endothelium. J Cell Physiol, 1989, 139, 570-579.
14. Giardino I, Edelstein M, Brownlee M. Non-enzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J Clin Invest, 1994, 94, 110-117.
15. Johnson D, Lee P, Lu J, Williams LT. Diverse forms of a receptor for acidic and basic fibroblast growth factors. Mol Cell Biol, 1991, 10, 4728-4736.
16. Givol D, Yayon A. Complexity of FGF receptors : genetic basis for structural diversity and functional specificity. FASEB J, 1992, 6, 3362-3369.
17. Steegmaler M, Levinovitz A, Isenmann S et al. The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor. Nature, 1995, 373, 615-620.
18. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989, 161, 851-856.
19. Connolly DT, Stoddard BL, Harakas NK, Feder J. Human fibroblast-derived growth factor is a mitogen and chemoattractant for endothelial cells. Biochem Biophys Res Commun, 1987, 144, 705-712.
20. Connolly DT, Olander JV, Heuvelman D et al. Human Vascular Permeability Factor. J Biol Chem. 1989, 264, 20017-20024.
21. Plouët J, Schilling J, Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by ATt20. EMBO J, 1989, 8, 3801-3806.
22. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 1989, 246, 1309-1312.
23. Leung DW, Cachianes G, Kuang WJ, Goeddel DW, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989, 246, 1306-1309.
24. Tischer E, Mitchell R, Hartman T et al. The human gene for vascular endothelial growth factor. J Biol Chem. 1991, 266, 11947-11954.
25. Houck K, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family : identification of a fourth molecular species and characterisation of alternative splicing of RNA. Molecular Endocrinol, 1991, 5, 1806-1814.
26. Favard C, Lamrani M, Chauvaud D, Gaudric A, Plouet J. Comparaison des activités angiogéniques de la vasculotropine et du facteur de croissance des fibroblastes. Ophtalmologie, 1992, 6, 118-121.
27. Favard C, Jonca F, Ruchoux M-M, Plouët J. Angiogenic potency of recombinant VEGF is dependent on its glycosylation. Invest Ophthalmol Vis Sci, 1994, 35 (Suppl).
28. Plouët J, Moukadiri H. Characterization of the receptor to vasculotropin on bovin adrenal cortex-derived capillary endothelial growth factor. J Biol Chem, 1990, 265, 22071-22074.
29. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for Vascular Endothelial Growth Factor. J Biol Chem, 1990, 265, 19461-19466.
30. Olander JV, De Larco JE, Connolly D. Specific binding of vascular factor to endothelial cells. Biochem Biophys Res Commun. 1991, 175, 68-76.
31. Terman BI, Vermazen MD, Carrion ME et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun, 1992, 34, 1578-1586.
32. Millauer B, Wizgmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell, 1993, 72, 835-846.
33. De Vries C, Escobedo J, Ueno H, Houck K, Ferrara N, Lewis LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 1992, 255, 989-991.
34. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood island formation and vasculogenesis in flk-1-deficient mice. Nature, 1995, 376, 62-66.
35. Fong G-H, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor in regulating the assembly of vascular endothelium. Nature, 1995, 376, 65-70.
36. Guerrin M, Moukadiri H, Chollet P et al. Vasculotropin vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells. J Cell Physiol. 1995, 164, 385-394.
37. Philips HS, Hains J, Leung D, Ferrara N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology, 1990, 127, 965-967.
38. Garrido C, Saule S, Gospodarewicz D. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Factors, 1993, 8, 109-117.
39. Jakeman LB, Winer J, Bennett GL, Altar A, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest, 1992, 89, 244-253.
40. Praloran V, Mirshahi S, Favard C, Moukadiri H, Plouet J. Mitogenic activity of vasculotropin for peripheral human lymphocytes. CR Acad Sci, 1991, 111, 21-26.
41. Lachgar S, Moukadiri H, Jonca F et al. Vascular endothelial growth factor is an autocrine growth factor for hair dermal papilla cells. J Invest Dermatol in press.
42. Courty J, Loret C, Moenner M, Courtois Y, Barritault D. Bovine retina contains three growth factor activities with a different affinity for heparin : eye-derived growth factor I, II, and II. Biochimie, 1985, 67, 265-269.
43. Malecaze F, Clamens S, Simorre-Pinatel V et al. Detection of VEGF mRNA and VAGf-like activity in proliferative diabetic retinopathy. Arch Ophthalmol, 1994, 112, 1476-1482.
44. Lewis GP, Guerin CJ, Erickson PA, Anderson DH, Fisher SK. Basic fibroblast growth factor (bFGF) stimulates proliferation of non-neuronal retinal cells in vivo. Invest Ophthalmol Vis Sci, 1991, 32 (Suppl), 754.
45. Schweigerer L, Malerstein B, Neufeld G, Gospodarowicz D. Basic fibroblast growth factor is synthesized in cultured retinal pigment epithelial cells. Biochem Biophys Res Comm, 1987, 143, 934-940.
46. Plouët J, Mascarelli F, Loret M-D, Faure J-P, Courtois Y. Regulation of eye-derived growth factor binding to membranes by light, ATP or GTP in photoreceptor outer segments. EMBO J, 1988, 7, 373-378.
47. Simorre-Pinatel V, Guerrin M, Chollet P et al. Vasculotropin/ Vascular Endothelial Growth Factors acts on retinal capillary endothelial cells through an autocrine pathway. Invest Ophthalmol Vis Sci, 1994, 35, 3393-3400.
48. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Diabetes, 1995, 42, 98-103.
49. Adamis AP, Miller JW, Bernal M-T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol, 1994, 118, 445-450.
50. Schweiki D, Itin A, Soffer D, Kehshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 1992, 359, 843-855.
51. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angioaenesis factor inhuman gliomas in vivo. Nature, 1992, 359, 845-848.
52. Shima DT, Adamis AP, Yeo KT, Yeo TK, Berse B, Brown L. Hypoxic regulation of vascular permeability factor (vascular endothelial growth factor) mRNA and protein secretion by human retinal pigment epithelial cells. Invest Ophthalmol Sci. 1993, 34 (Suppl), 990.
53. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Archivs, 1995, 426, 479-486.
54. Lutty G, McLeod DS, Merges C, Diggs A, Plouët J. Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthal, in press.
55. Tolentino MJ, Miller JW, Gragoudas ES et al. Vascular endothelial growth factor is sufficient to produce ocular neovascularization in a non-human primate. Invest Ophthalmol Vis Sci, 1995, 36 (Suppl), S402.
56. Miller JW, Adamis AP, Shima DT et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spacially correlated with ocular angiogenesis in a primate model. Am J Pathol, 1994, 145, 574-584.
57. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci. 1995, 92, 905-909.
58. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of the prematurity. Nature Med, 1995, 1, 1024-1028.
59. Pournaras CJ, Tsacopoulos M, Strommer K, Gilodi N, Leuenberger PM. Scatter panretinal photocoagulation restores tissue hypoxia in experimental vasoproliferative microangiopathy in miniature pigs. Ophthalmology, 1990, 97, 1329-1333.
60. Sivalingam A, Kenny J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor level in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol, 1990, 108, 869-872.
61. Hanneken A, De Juan E Jr, Lutty G. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol, 1991, 109, 1005-1011.
62. Aiello LP, Avery RL, Arrig PG. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal diseases. New Engl J Med, 1994, 331, 1480-1487.
63. Miller JW, Shima DT, Tolentino M et al. Inhibition of VEGF prevents ocular angiogenesis in a primate model. Am J Pathol, 1994, 145, 574-584.
64. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric protein. Proc Natl Acad Sci, 1995, 92, 10457-10461.
65. Hu DE, Fan T-PD. Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavenstudin. A Br J Pharm. 1995, 114, 262-268.
66. Brooks PC, Montgomery AMP, Rosenfeld M et al. Integrin avb3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79, 1157-1164.